5
Total investments
1
Early stage
2
Mid stage
2
Late stage
9y
Years active
Portfolio
5 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Board Member
Mar 2021
Personalised cancer therapeutics platform pioneered at Mount Sinai Medical Center
Board Member
Mar 2021
Built by scientists, for scientists. Labstep is a digital research platform that allows researchers to collect, manage and share data securely in the cloud. With Labstep, lab management of reagents and equipment becomes easy and intuitive, allowing scientists to stay on top of their research.
Our main objective is to allow scientists to spend more time researching and less time on data administration. Labstep is also tackling major issues faced by researchers around reproducibility of results. Over half of all scientific results published cannot be reproduced. To make data more reproducible, we allow real-time scientific data tracking for all researchers, thereby adding value to scientific output.
Board Member
Dec 2018
Andela was created with one thing in mind: Brilliance is evenly distributed, but opportunity isn’t. Our platform bridges that gap. We specialize in helping our highly-skilled, global technology talent community in emerging markets, connect with hundreds of leading companies like InVision, Cloudflare, and ViacomCBS who leverage Andela to scale their technology teams quickly and cost-effectively. Our talent spans six continents and Andela is backed by investors including Generation Investment Management, SoftBank, Chan Zuckerberg Initiative, Spark Capital, and Google Ventures.
Board Member
Dec 2018
SOPHiA GENETICS was founded in 2011 by biologists who had a vision to create a technology that could make a positive and lasting impact on the world, using data for good.
We’ve built a revolutionary technology platform, SOPHiA DDM™, that rapidly distills complex data into actionable insights, enabling clinicians, researchers, and biopharma to reshape the way that we diagnose and treat cancer and rare inherited disorders.
The AI fueling our platform learns from the complex genomic and multimodal data provided by our community of users to create a collective intelligence over time. By using the power of data and AI, we are expanding access to data-driven medicine and enabling the patients of today to help the patients of tomorrow.
Our science is driven by unrelenting passion for our mission to transform patient care by expanding access to data-driven medicine globally.
We wouldn’t be able to achieve all that we have – and all that we will – without our people, who are driven by our shared purpose to ensure that every patient worldwide has equitable access to precision medicine.
Our virtues are our behaviors we exhibit every day, and our mantra “We Care” is our driving force.
Board Observer
Mar 2017
CIBO is a breakthrough technology platform that accelerates regenerative agriculture and is the first, direct-from-the-farmer carbon marketplace. CIBO starts from the ground up and scales to county, state and national levels without requiring expensive or complex data from farmers. CIBO’s insights include land and lease values, productivity, soil stability, sustainability, yield forecasts, and more.
Experience · 10 entries
All (10)
Investments (5)
Founder (1)
Board (5)
2021
Co-founder | CEO
Oct 2021
Synteny’s techbio platform decodes the signal of immune repertoires to power disease discoveries.
Board Member
Mar 2021
Personalised cancer therapeutics platform pioneered at Mount Sinai Medical Center
Board Member
Mar 2021
Built by scientists, for scientists. Labstep is a digital research platform that allows researchers to collect, manage and share data securely in the cloud. With Labstep, lab management of reagents and equipment becomes easy and intuitive, allowing scientists to stay on top of their research.
Our main objective is to allow scientists to spend more time researching and less time on data administration. Labstep is also tackling major issues faced by researchers around reproducibility of results. Over half of all scientific results published cannot be reproduced. To make data more reproducible, we allow real-time scientific data tracking for all researchers, thereby adding value to scientific output.
2018
Board Member
Dec 2018
Andela was created with one thing in mind: Brilliance is evenly distributed, but opportunity isn’t. Our platform bridges that gap. We specialize in helping our highly-skilled, global technology talent community in emerging markets, connect with hundreds of leading companies like InVision, Cloudflare, and ViacomCBS who leverage Andela to scale their technology teams quickly and cost-effectively. Our talent spans six continents and Andela is backed by investors including Generation Investment Management, SoftBank, Chan Zuckerberg Initiative, Spark Capital, and Google Ventures.
Board Member
Dec 2018
SOPHiA GENETICS was founded in 2011 by biologists who had a vision to create a technology that could make a positive and lasting impact on the world, using data for good.
We’ve built a revolutionary technology platform, SOPHiA DDM™, that rapidly distills complex data into actionable insights, enabling clinicians, researchers, and biopharma to reshape the way that we diagnose and treat cancer and rare inherited disorders.
The AI fueling our platform learns from the complex genomic and multimodal data provided by our community of users to create a collective intelligence over time. By using the power of data and AI, we are expanding access to data-driven medicine and enabling the patients of today to help the patients of tomorrow.
Our science is driven by unrelenting passion for our mission to transform patient care by expanding access to data-driven medicine globally.
We wouldn’t be able to achieve all that we have – and all that we will – without our people, who are driven by our shared purpose to ensure that every patient worldwide has equitable access to precision medicine.
Our virtues are our behaviors we exhibit every day, and our mantra “We Care” is our driving force.
Show all 10 entries ↓
Investment activity
2017–2021 · 5 investments
Recent (last 2 years)Earlier
